Top Markets
Coin of the day
Alpha Cognition Inc Alpha Cognition Inc

Alpha Cognition Inc

ACOG
Rangering i aksjer #19835
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aksjekurs
$9.61
Sist synkronisert: 2026-08-25
Markedsverdi
$149.33M
Endring (1 dag)
-1.39%
Endring (1 år)
21.24%
Land
US
Handel Alpha Cognition Inc (ACOG)

Kategori

P/B-forhold for Alpha Cognition Inc (ACOG)
P/B-forhold per 2026 TTM: 0
Ifølge Alpha Cognition Inc sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Alpha Cognition Inc fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH